RHHBF - Roche: Value Remains Despite Covid-19 Revenue Growth Loss

2024-04-28 05:44:58 ET

Summary

• Vabysmo and Phesgo are still strong growth drivers for the company going forward, growing year over year in Q1 of 2024 by 108% and 70%, respectively.
• Mid-single digit sales growth is expected to remain with the pipeline that it has established thus far, with several data readouts expected in 2024 to drive additional shareholder value.
• Ocrevus is expected to remain as the best-selling Multiple Sclerosis Drug in 2030, generating approximately $6.3 billion in sales.
• The acquisition of Carmot Therapeutics brought on board three drugs that could be used to target the large obesity drugs market space, which are CT-388, CT-996 and CT-868. Such drugs target the GLP-1 and/or GIP proteins to treat such patients.

Roche ( RHHBY )( RHHBF )( RHHVF ) still has good long-term prospects since the last time I wrote an article about it. This was with respect to an article entitled "Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender". In this article, I noted that this company had good long-term value with Ocrevus, which has been approved to treat patients with multiple sclerosis [MS]. Plus, that it was working on another drug for its pipeline, known as Fenebrutinib, which is also being advanced for the treatment of patients with MS. However, in the case of this drug, it is specifically targeting patients with relapsing MS and primary progressive MS. There is value here with Fenebrutinib because results from a phase 3 study using it to treat both of these patient populations is expected to be released in 2025. Thus, the value of both Ocrevus sales increasing, plus the promising of Fenebrutinib, still hold true....

For further details see: